Table 2 |
|||||
|
Safety and efficacy variables of the study presented as mean and difference in means (95% confidence interval) |
|||||
|
N |
APC |
Placebo |
Difference in means between the study groups (95% CI) |
||
|
|
|||||
|
Delta SOFA score |
16 |
1.8 (4.3) |
16 |
-0.6 (4.1) |
2.3 (-0.7 to 5.2) |
|
Delta-non-hepatic SOFA |
16 |
1.9 (4.1) |
16 |
-0.2 (3.9) |
2.1 (-0.8 to 4.9) |
|
Ventilator free days |
16 |
10.4 (9.4) |
16 |
10.4 (11.5) |
0 (-7.4 to 7.4) |
|
Renal replacement therapy-free days |
16 |
52.7 (12.7) |
16 |
55.3 (9.3) |
-2.6 (-10.5 to 5.3) |
|
Vasopressor-free days |
16 |
52.8 (7.1) |
16 |
55.1 (6.0) |
-2.6 (-5.9 to 2.3) |
|
Alive outside hospital - days |
16 |
17.1 (32.5) |
16 |
34.4 (13.0) |
-17.4 (-0.1 to -34.9) |
|
Delta modified CT score |
11 |
0.5 (2.0) |
11 |
0.5 (1.8) |
0 (-1.6 to 1.6) |
|
Delta serum bilirubin, total (μmol/L) |
16 |
18 (46.4) |
16 |
-10 (17.0) |
28 (3.6 to 53.1) * |
|
Delta serum bilirubin, conjugated (μmol/L) |
13 |
14 (31.9) |
12 |
-11 (11.1) |
25 (5.6 to 44.4) * |
|
Delta serum creatinine (μmol/L) |
16 |
-37 (84) |
16 |
13 (86) |
-50 (-110 to 10) |
|
Delta platelet count (× 109/L) |
16 |
32 (52) |
16 |
35 (55) |
-3 (-40 to 34) |
|
Delta plasma hemoglobin mg/L |
13 |
-226 (499.5) |
16 |
-65 (83.2) |
-161 (-413 to 92.0) |
|
Delta serum pre-albumin mg/L |
13 |
-50 (49.7) |
12 |
-69 (55.2) |
19 (-23.0 to 61.0) |
|
|
|||||
|
Organ-dysfunction-free days calculated for 60 days. *significant differences; CI, confidence interval. |
|||||
|
Pettilä et al. Critical Care 2010 14:R139 doi:10.1186/cc9203 |
|||||
